BAL PHARMA
Quarterly Results Analysis [Dec2024]
BAL PHARMA Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 Audited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹73 Cr | ₹74 Cr | ₹74 Cr | ₹95 Cr | ₹82 Cr | ₹93 Cr | ₹70 Cr | ₹82 Cr |
Expenses | ₹65 Cr | ₹66 Cr | ₹68 Cr | ₹85 Cr | ₹74 Cr | ₹85 Cr | ₹64 Cr | ₹74 Cr |
Operating Income | ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹8 Cr |
Other Income | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Interest | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
Depreciation | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
Profit Before Tax | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹6 Cr | ₹1 Cr | ₹2 Cr | ₹0 Cr | ₹2 Cr |
Profit After Tax | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹6 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr |
EPS | ₹0.30 | ₹0.65 | ₹0.16 | ₹3.46 | ₹0.56 | ₹0.60 | ₹0.05 | ₹1.02 |
Industry Peers & Returns | 1W | 1M | 1Y |
BAL PHARMA | 0.1% | 26.9% | 2.9% |
SUN PHARMACEUTICAL INDUSTRIES | 6% | 4% | 9.9% |
DIVIS LABORATORIES | 4.7% | 0.3% | 52.4% |
CIPLA | 7% | 3.7% | 7.2% |
TORRENT PHARMACEUTICALS | 4.1% | 6.4% | 25% |
DR REDDYS LABORATORIES | 6.3% | 5% | -4.7% |
MANKIND PHARMA | 11.6% | 17.3% | 8.8% |
ZYDUS LIFESCIENCES | -1.6% | -5.8% | -14.5% |
LUPIN | 0.8% | -1.6% | 19.3% |
BAL PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -0.73 % |
Y-o-Y | -10.42 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹73 Cr | -0.73 | |
Sep2024 | ₹74 Cr | -0.89 | |
Jun2024 | ₹74 Cr | -21.42 | |
Mar2024 | ₹95 Cr | 15.87 | |
Dec2023 | ₹82 Cr | -11.76 | |
Sep2023 | ₹93 Cr | 31.48 | |
Jun2023 | ₹70 Cr | -14.63 | |
Mar2023 | ₹82 Cr | - |
BAL PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 0.82 % |
Y-o-Y | -0.47 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹8 Cr | 0.82 | |
Sep2024 | ₹8 Cr | 19.03 | |
Jun2024 | ₹6 Cr | -32.60 | |
Mar2024 | ₹10 Cr | 23.05 | |
Dec2023 | ₹8 Cr | 1.26 | |
Sep2023 | ₹8 Cr | 19.46 | |
Jun2023 | ₹6 Cr | -21.07 | |
Mar2023 | ₹8 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 1.63 % |
Y-o-Y | 11.10 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 10.61% | 1.63 | |
Sep2024 | 10.44% | 20.14 | |
Jun2024 | 8.69% | -14.30 | |
Mar2024 | 10.14% | 6.18 | |
Dec2023 | 9.55% | 14.78 | |
Sep2023 | 8.32% | -9.17 | |
Jun2023 | 9.16% | -7.47 | |
Mar2023 | 9.9% | - |
BAL PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -50.05 % |
Y-o-Y | -38.87 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹1 Cr | -50.05 | |
Sep2024 | ₹1 Cr | 301.16 | |
Jun2024 | ₹0 Cr | -95.32 | |
Mar2024 | ₹6 Cr | 551.59 | |
Dec2023 | ₹1 Cr | -12.47 | |
Sep2023 | ₹1 Cr | 921.05 | |
Jun2023 | ₹0 Cr | -94.13 | |
Mar2023 | ₹2 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -49.65 % |
Y-o-Y | -31.73 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 0.71 % | -49.65 | |
Sep2024 | 1.41 % | 302.86 | |
Jun2024 | 0.35 % | -94.02 | |
Mar2024 | 5.85 % | 462.50 | |
Dec2023 | 1.04 % | -0.95 | |
Sep2023 | 1.05 % | 707.69 | |
Jun2023 | 0.13 % | -93.37 | |
Mar2023 | 1.96 % | - |
BAL PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -53.85 % |
Y-o-Y | -46.43 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹0.3 | -53.85 | |
Sep2024 | ₹0.65 | 306.25 | |
Jun2024 | ₹0.16 | -95.38 | |
Mar2024 | ₹3.46 | 517.86 | |
Dec2023 | ₹0.56 | -6.67 | |
Sep2023 | ₹0.6 | 1,100.00 | |
Jun2023 | ₹0.05 | -95.10 | |
Mar2023 | ₹1.02 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD